{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:04:54Z","timestamp":1794049494848,"version":"4.8.0"},"reference-count":149,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/19420862.2024.2443538","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T02:56:43Z","timestamp":1734922603000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":192,"title":["Antibodies to watch in 2025"],"prefix":"10.1080","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-5957","authenticated-orcid":false,"given":"Silvia","family":"Crescioli","sequence":"first","affiliation":[{"name":"The Antibody Society, Inc","place":["Framingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-2195","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Kaplon","sequence":"additional","affiliation":[{"name":"Institut de Recherches Internationales Servier","place":["Gif-sur-Yvette, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7958-9894","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-2438","authenticated-orcid":false,"given":"Jyothsna","family":"Visweswaraiah","sequence":"additional","affiliation":[{"name":"Seismic Therapeutic","place":["Watertown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-1487","authenticated-orcid":false,"given":"Vaishali","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis School of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-1951","authenticated-orcid":false,"given":"Janice M.","family":"Reichert","sequence":"additional","affiliation":[{"name":"The Antibody Society, Inc","place":["Framingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"Taylor & Francis. Antibodies to watch collection. 2024 Jan 23. [accessed 2024 Nov 16]. https:\/\/www.tandfonline.com\/journals\/kmab20\/collections\/antibodies-to-watch."},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2297450"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2153410"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.2014296"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1860476"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1703531"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1556465"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.268"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0708"},{"key":"e_1_3_5_11_1","unstructured":"Eli Lilly and Company. Lilly\u2019s Kisunla\u2122 (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer\u2019s disease. 2024 Jul 2 press release. [accessed 2024 Nov 10]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early."},{"key":"e_1_3_5_12_1","unstructured":"Eli Lilly and Company. Lilly\u2019s Kisunla\u2122 (donanemab-azbt) approved in Japan for the treatment of early symptomatic Alzheimer\u2019s disease. 2024 Sep 24 press release [accessed 2024 Nov 10]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-approved-japan-treatment-early."},{"key":"e_1_3_5_13_1","unstructured":"Eli Lilly and Company. Lilly\u2019s Kisunla\u2122 (donanemab-azbt) receives marketing authorization in Great Britain for the treatment of mild cognitive impairment and mild dementia due to Alzheimer\u2019s disease in adult patients who are apolipoprotein E \u03954\u00a0heterozygotes or non-carriers. 2024 Oct 23 press release [accessed 2024 Nov 10]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-kisunlatm-donanemab-azbt-receives-marketing-authorization."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_5_15_1","unstructured":"Eli Lilly and Company. Modified titration of donanemab demonstrated reduction of ARIA-E in early symptomatic Alzheimer\u2019s disease patients in phase 3b study. 2024 Oct 29 press release [accessed 2024 Nov 11]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/modified-titration-donanemab-demonstrated-reduction-aria-e-early."},{"key":"e_1_3_5_16_1","unstructured":"Incyte. Syndax pharmaceuticals. Incyte and syndax announce U.S. FDA approval of Niktimvo\u2122 (axatilimab-csfr) for the treatment of chronic graft-versus-Host disease (GVHD). 2024 Aug 14 press release [accessed 2024 Sep 8]. https:\/\/ir.syndax.com\/news-releases\/news-release-details\/incyte-and-syndax-announce-us-fda-approval-niktimvotm-axatilimab."},{"key":"e_1_3_5_17_1","unstructured":"US Food and Drug Administration. Highlights of prescribing information for NIKTIMVO\u2122 (axatilimab-csfr). [accessed 2024 Sep 8]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761411s000lbl.pdf."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401537"},{"key":"e_1_3_5_19_1","unstructured":"Pfizer Inc. U.S. FDA approves Pfizer\u2019s HYMPAVZI\u2122 (marstacimab-hncq) for the treatment of adults and adolescents with hemophilia a or B without inhibitors. 2024 Oct 11 [accessed 2024 Nov 2]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-hympavzitm-marstacimab-hncq."},{"key":"e_1_3_5_20_1","unstructured":"Pfizer. European commission approves Pfizer\u2019s HYMPAVZI\u2122 (marstacimab) for the treatment of adults and adolescents with severe hemophilia a or B without inhibitors. 2024 Nov 20 press release [accessed 2024 Nov 20]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european-commission-approves-pfizers-hympavzitm-marstacimab."},{"key":"e_1_3_5_21_1","unstructured":"Chugai Pharmaceuticals. Crovalimab approved in China as the first country for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). 2024 Feb 8 press release [accessed 2024 Nov 12]. https:\/\/www.chugaipharm.co.jp\/english\/news\/detail\/20240208113000_1047.html."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02032-5"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27413"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27412"},{"key":"e_1_3_5_25_1","unstructured":"US Food and Drug Administration. FDA approves zolbetuximab-clzb with chemotherapy for gastric or gastroesophageal junction adenocarcinoma. 2024 Oct 18 press release. [accessed 2024 Oct 18]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma."},{"key":"e_1_3_5_26_1","unstructured":"Amgen. FDA approves imdelltra\u2122 (tarlatamab-dlle) the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer. 2024 May 16 press release. [accessed 2024 Nov 12]. https:\/\/www.amgen.com\/newsroom\/press-releases\/2024\/05\/fda-approves-imdelltra-tarlatamabdlle-the-first-and-only-tcell-engager-therapy-for-the-treatment-of-extensivestage-small-cell-lung-cancer."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980"},{"key":"e_1_3_5_28_1","unstructured":"Amgen. Amgen presents new data for first-in-class Imdelltra\u2122 (tarlatamab-dlle) in small cell lung cancer at WCLC 2024. 2024 Sep 9 press release. [accessed 2024 Nov 12]. https:\/\/www.amgen.com\/newsroom\/press-releases\/2024\/09\/amgen-presents-new-data-for-firstinclass-imdelltra-tarlatamabdlle-in-small-cell-lung-cancer-at-wclc-2024."},{"key":"e_1_3_5_29_1","unstructured":"Jazz Pharmaceuticals Announces U.S. FDA approval of Ziihera\u00ae (zanidatamab-hrii) for the treatment of adults with Previously treated unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). 2024 Nov 20 press release. [accessed 2024 Nov 12]. https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-approval-ziiherar."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"e_1_3_5_31_1","unstructured":"Merus NV. Merus announces FDA approval of BIZENGRI\u00ae (zenocutuzumab-zbco) for NRG1+ pancreatic adenocarcinoma and NRG1+ Non\u2013Small Cell Lung cancer (NSCLC) based on safety and efficacy data from the eNRGY study. 2024 Dec 4 press release. [accessed 2024 Dec 5]. https:\/\/ir.merus.nl\/news-releases\/news-release-details\/merus-announces-fda-approval-bizengrir-zenocutuzumab-zbco-nrg1."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0824"},{"key":"e_1_3_5_33_1","unstructured":"Merus NV. Merus corporate presentation. 2024 Sep [accessed 2024 Nov 6]. https:\/\/ir.merus.nl\/static-files\/909329a7-7cf3-44c4-878b-ae9bf61ce711."},{"key":"e_1_3_5_34_1","unstructured":"Regeneron Pharmaceuticals Inc. Ordspono\u2122 (odronextamab) approved in the European Union for the treatment of Relapsed\/Refractory follicular lymphoma and diffuse large B-cell lymphoma. 2024 Aug 26 press release. [accessed 2024 Nov 2]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/ordsponotm-odronextamab-approved-european-union-treatment\/."},{"key":"e_1_3_5_35_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron Provides Update on Biologics License Application for Odronextamab. 2024 Mar 25 press release. [accessed 2024 Nov 2]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-provides-update-biologics-license-application\/."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.066"},{"key":"e_1_3_5_37_1","unstructured":"Jiangsu Hengrui Pharmaceuticals Co. Ltd. Milestone in chronic disease Innovation! Hengrui\u2019s first innovative autoimmune drug vunakizumab. Approved for market launch. 2024 Aug 27 press release. [accessed 2024 Oct 14]. https:\/\/www.hengrui.com\/media\/detail-618.html."},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.09.031"},{"key":"e_1_3_5_39_1","unstructured":"Chongqing Genrix Biopharmaceutical Co. Ltd. China\u2019s first! Genrix Bio\u2019s independently developed fully humanized anti-IL-17A monoclonal antibody xeligekimab has been approved for market authorization. 2024 Aug 27 press release. [accessed 2024 Oct 14]. http:\/\/www.genrixbio.com\/#\/article_details?id=47."},{"key":"e_1_3_5_40_1","unstructured":"Chongqing Genrix Biopharmaceutical Co. Ltd. Genrix Bio\u2019s market authorization application for xeligekimab injection for the indication of axial spondyloarthritis has been accepted by the NMPA. 2024 Jan 4 press release. [accessed 2024 Oct 14]. http:\/\/www.genrixbio.com\/#\/article_details?id=32."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae062"},{"key":"e_1_3_5_42_1","unstructured":"Keymed Biosciences Inc. Stapokibart was granted marketing approval from national medical products administration for the treatment of moderate-to-severe atopic dermatitis in Adults.12. 2024 Sep [accessed 2024 Oct 24]. https:\/\/www.biospace.com\/press-releases\/stapokibart-was-granted-marketing-approval-from-national-medical-products-administration-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-in-adults."},{"key":"e_1_3_5_43_1","unstructured":"Keymed Biosciences Inc. Voluntary announcement: CM310 phase III clinical trial topline data accepted for poster session at the 2023 European Academy of dermatology and venereology (EADV) congress. 2023 Oct 11 press release. [accessed 2024 Oct 1]. https:\/\/www.keymedbio.com\/show-132-208-1.html."},{"key":"e_1_3_5_44_1","unstructured":"Akeso. Akeso\u2019s ebronucimab (PCSK9) approved for two indications for the treatment of hypercholesterolemia in China. 2024 Sep 30 press release. [accessed 2024 Oct 19]. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/akeso-s-ebronucimab-pcsk9-approved-for-two-indications-for-the-treatment-of-hypercholesterolemia-in-china\/."},{"key":"e_1_3_5_45_1","unstructured":"Akeso. NMPA accepted Akeso\u2019s ebronucimab (PCSK9) marketing application in two indications. 2024 June 2 press release. [accessed 2024 Oct 19]. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/230602\/."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107340"},{"key":"e_1_3_5_47_1","unstructured":"Shanghai Junshi Biosciences Co. Ltd. Junshi biosciences announces Ongericimab\u2019s NDA approval in China. 2024 Oct 12 press release. [accessed 2024 Oct 15]. https:\/\/www.junshipharma.com\/en\/\u541b\u5b9e\u751f\u7269\u5ba3\u5e03\u6602\u6208\u745e\u897f\u5355\u6297\uff08\u541b\u9002\u8fbe\uff09\u5728\u4e2d\u56fd\u83b7\/."},{"key":"e_1_3_5_48_1","unstructured":"CSPC Pharmaceutical Group Ltd. Enlonstobart injection obtains conditional marketing approval granted by NMPA. 2024 June 28 press release. [accessed 2024 Oct 10]. https:\/\/doc.irasia.com\/listco\/hk\/cspc\/announcement\/a240628b.pdf."},{"key":"e_1_3_5_49_1","unstructured":"Hangzhou Sumgen Biotech Co. Ltd. Major milestone! Enlonstobart injection (Enshuxin\u00ae) approved for listing domestically! 2024 June 28 press release. [accessed 2024 Oct 20]. https:\/\/sumgenbio.com\/en\/?c=Service&a=nav&id=364."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.5526"},{"key":"e_1_3_5_51_1","unstructured":"Qilu Puget Sound Biotherapeutic Corp. Sound biologics announces breakthrough approval of PSB205 by the national medical products administration in China. 2024 Oct 16 press release. [accessed 2024 Oct 19]. https:\/\/www.einpresswire.com\/article\/751512407\/sound-biologics-announces-breakthrough-approval-of-psb205-by-the-national-medical-products-administration-in-china?n=2."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-ESGO.8"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6026"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01731-x"},{"key":"e_1_3_5_55_1","unstructured":"Sino Biopharmaceutical Ltd. Interim report. 2024 [accessed 2024 Oct 24]. https:\/\/www.sinobiopharm.com\/userfiles\/files\/E24071768-Sino%20Bio-IR24.pdf."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03132-1"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613"},{"key":"e_1_3_5_58_1","unstructured":"Akeso. WCLC. Akeso\u2019s ivonescimab head-to-head phase III data against pembrolizumab unveiled. 2024 Sep 8 press release. [accessed 2024 Sep 9]. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/240908\/."},{"key":"e_1_3_5_59_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Core product sacituzumab tirumotecan (sac-tmt) approved for marketing by the national medical products administration for 2L+ TNBC based on OptiTROP-Breast01 study. 2024 Nov 27 press release. [accessed 2024 Nov 27]. https:\/\/iis.aastocks.com\/20241127\/11452579-0.PDF."},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.104"},{"key":"e_1_3_5_61_1","unstructured":"Biocad. \u0412 \u0420\u043e\u0441\u0441\u0438\u0438 \u0437\u0430\u0440\u0435\u0433\u0438\u0441\u0442\u0440\u0438\u0440\u043e\u0432\u0430\u043b\u0438 \u043f\u0435\u0440\u0432\u044b\u0439 \u0432 \u043c\u0438\u0440\u0435 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 \u0441\u043f\u043e\u0441\u043e\u0431\u043d\u044b\u0439 \u043e\u0441\u0442\u0430\u043d\u043e\u0432\u0438\u0442\u044c \u0440\u0430\u0437\u0432\u0438\u0442\u0438\u0435 \u0431\u043e\u043b\u0435\u0437\u043d\u0438 \u0411\u0435\u0445\u0442\u0435\u0440\u0435\u0432\u0430 (translation: The world\u2019s first drug capable of stopping the development of ankylosing spondylitis has been registered in Russia). 2024 May 1 press release. [accessed 2024 Sep 7]. https:\/\/biocad.ru\/news\/v-rossii-zaregistrirovali-pervyj-v-mire-preparat-sposobnyj-ostanovit-razvitie-bolezni-behtereva."},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.47360\/1995-4484-2024-65-80"},{"key":"e_1_3_5_63_1","unstructured":"SFJ Pharmaceuticals. FDA has accepted a BLA for bentracimab the first and only ticagrelor reversal agent for filing and priority review. 2024 Aug 2 press release. [accessed 2024 Nov 2]. https:\/\/serb.com\/news\/fda-has-accepted-a-bla-for-bentracimab-the-first-and-only-ticagrelor-reversal-agent-for-filing-and-priority-review\/."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100047"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2024.07.001"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.818"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16351"},{"key":"e_1_3_5_68_1","unstructured":"CSL. Research & Development Investor Briefing. 2024 presentation. [Oct 22 [accessed 2024 Nov 8]. https:\/\/investors.csl.com\/pdf\/15cfdb5c-f8e2-4d90-8243-1253071853af\/Research-and-Development-Investor-Briefing.pdf."},{"key":"e_1_3_5_69_1","unstructured":"Johnson & Johnson. Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis. 2024 Aug 29 press release. [accessed 2024 Sep 21]. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-seeks-first-approval-of-nipocalimab-to-treat-broadest-population-living-with-antibody-positive-generalized-myasthenia-gravis."},{"key":"e_1_3_5_70_1","unstructured":"Johnson & Johnson. Johnson & Johnson seeks first EU approval of nipocalimab to treat a broad population of patients living with antibody-positive generalised myasthenia gravis. 2024 Sep 12 press release. [accessed 2024 Sep 21]. https:\/\/s203.q4cdn.com\/636242992\/files\/doc_news\/2024\/Sep\/12\/jj-emea_nipocalimab_ema-mg-filing_pr_final_120924.pdf."},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.33590\/emjneurol\/BTET5689"},{"key":"e_1_3_5_72_1","unstructured":"European Medicines Agency. CHMP summary of positive opinion for gohibic. 2024 Nov 14 [accessed 2024 Nov 18]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gohibic."},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.1369"},{"key":"e_1_3_5_74_1","unstructured":"AstraZeneca. Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention. 2024 Jul 1 press release. [accessed 2024 Nov 2]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention.html."},{"key":"e_1_3_5_75_1","unstructured":"AstraZeneca. SUPERNOVA phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population. 2024 May 16 press release. [accessed 2024 Nov 20]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/supernova-trial-met-covid-19-prevention-endpoint.html."},{"key":"e_1_3_5_76_1","unstructured":"Merck. Merck\u2019s clesrovimab (MK-1654) an investigational respiratory syncytial virus (RSV) preventative monoclonal antibody significantly reduced incidence of RSV disease and hospitalization in healthy preterm and full-term infants. 2024 Oct 17 press release. [accessed 2024 Oct 19]. https:\/\/www.merck.com\/news\/mercks-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-rsv-preventative-monoclonal-antibody-significantly-reduced-incidence-of-rsv-disease-and-hospitalization-in-heal\/."},{"key":"e_1_3_5_77_1","unstructured":"Omeros Corporation. Omeros corporation provides update on progress toward BLA resubmission. 2024 Nov 21 press release. [accessed 2024 Dec 2]. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-provides-update-progress-toward-bla."},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.07.035"},{"key":"e_1_3_5_79_1","unstructured":"Castro A. Recaticimab effective as add-on therapy in non-familial hypercholesterolemia and mixed hyperlipidemia: REMAIN-2 trial. Cardiology Now News. 2023 Nov 13 [accessed 2024 Oct 20]. https:\/\/cardiologynownews.org\/recaticimab-effective-as-add-on-therapy-in-non-familial-hypercholesterolaemia-and-mixed-hyperlipidemia-remain-2-trial\/."},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(24)03697-0"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100820"},{"key":"e_1_3_5_82_1","unstructured":"SinoMab BioScience Limited. Interim results announcement for the six months ended 30 June 2024 and change in use of proceeds. 2024 Aug 19 press release. [accessed 2024 Oct 19]. https:\/\/www.hkexnews.hk\/listedco\/listconews\/sehk\/2024\/0819\/2024081901314.pdf."},{"key":"e_1_3_5_83_1","unstructured":"Zhuhai Trinomab Biotech Co. Ltd. A first-in-class anti-tetanus monoclonal antibody TNM002 in the world is filed for NDA. 2023 Dec 7 press release. [accessed 2024 Oct 10]. https:\/\/www.trinomab.com\/en-us\/info\/469.html."},{"key":"e_1_3_5_84_1","unstructured":"Changchun GeneScience Pharmaceuticals Co. Ltd. R&D progress: NMPA approves genakumab to the market. 2024 Apr 11 press release. [accessed 2024 Oct 10]. https:\/\/www.genscigroup.com\/en\/news\/media\/137."},{"issue":"9","key":"e_1_3_5_85_1","article-title":"Efficacy and safety of genakumab versus compound betamethasone in gout: the GUARD-1 study [abstract]","volume":"76","author":"Xue Y","year":"2024","unstructured":"Xue Y, Chu T, Hu J, Gou W, Zhang N, Li J, Yu J, Li S, Li S, Qian L, et al. Efficacy and safety of genakumab versus compound betamethasone in gout: the GUARD-1 study [abstract]. Arthritis Rheumatol. 2024;76(suppl 9). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-genakumab-versus-compound-betamethasone-in-gout-the-guard-1-study\/.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_86_1","unstructured":"Innovent Biologics Inc. Innovent announces the new drug application of IBI311 (IGF-1R antibody) has been accepted by the NMPA of China for thyroid eye disease. 2024 May 21 press release. [accessed 2024 Oct 9]. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=449."},{"key":"e_1_3_5_87_1","unstructured":"Innovent Biologics Inc. Innovent announces primary endpoint met in the phase 3 clinical trial (RESTORE-1) of IBI311 (anti-IGF-1R antibody) in treating thyroid eye disease and plans to submit NDA to the NMPA. 2024 Feb 20 press release. [accessed 2024 Oct 9]. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=431."},{"key":"e_1_3_5_88_1","unstructured":"Harbour BioMed. Harbour BioMed announces resubmission of biologics license application for batoclimab to NMPA for treatment of generalized myasthenia gravis. 2024 June 27 press release. [accessed 2024 Oct 14]. https:\/\/www.harbourbiomed.com\/news\/222.html."},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0044"},{"key":"e_1_3_5_90_1","volume-title":"European Academy of Dermatology and Venereology Congress 2024, Amsterdam, 25 Sep \u2013 28 Sep, 2024","author":"Zhang J","unstructured":"Zhang J, Zhang L, Wang G, Xia Y, Wang M, Li B. Long-term safety and efficacy of ebdarokimab in patients with moderate to severe plaque psoriasis: results from a single arm, open label, multicenter phase III clinical study. Abstract 982. European Academy of Dermatology and Venereology Congress 2024, Amsterdam, 25 Sep \u2013 28 Sep, 2024; accessed 2024 Oct 19]. https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.eadv\/abstracts_congress_2024\/42456.pdf."},{"key":"e_1_3_5_91_1","unstructured":"Innovent Biologics Inc. Innovent announces NMPA acceptance of NDA for picankibart (anti-IL-23p19 antibody) for treating moderate to severe plaque psoriasis. 2024 Sep 26 press release. [accessed 2024 Sep 26]. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=486."},{"key":"e_1_3_5_92_1","unstructured":"Innovent Biologics Inc. Innovent announces picankibart (IBI112) achieved primary endpoints in a phase 3 clinical trial in treating moderate to severe plaque psoriasis and plans to submit NDA to the NMPA. 2024 May 28 press release. [accessed 2024 Aug 29]. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=450."},{"key":"e_1_3_5_93_1","unstructured":"3SBio.2024 interim results presentation. 2024 Aug 23 [accessed 2024 Aug 28]. https:\/\/www.3sbio.com\/ImgUpload\/files\/202408\/2024082206302528344.pdf."},{"key":"e_1_3_5_94_1","unstructured":"Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab. 2024 Jul 2 press release. [accessed 2024 Nov 2]. https:\/\/ir.checkpointtx.com\/news-events\/press-releases\/detail\/119\/checkpoint-therapeutics-announces-biologics-license."},{"key":"e_1_3_5_95_1","unstructured":"Checkpoint therapeutics announces FDA acceptance of BLA resubmission of cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma. 2024 Jul 25 [accessed 2024 Nov 2]. https:\/\/ir.checkpointtx.com\/news-events\/press-releases\/detail\/122\/checkpoint-therapeutics-announces-fda-acceptance-of-bla."},{"key":"e_1_3_5_96_1","unstructured":"AstraZeneca. Datopotamab deruxtecan biologics license application accepted in the US for patients with previously treated metastatic hr-positive HER2-negative.Breast cancer. 2024 Apr 2 press release [accessed 2024 Nov 10]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/fda-accepts-dato-dxd-bla-for-breast-cancer.html."},{"key":"e_1_3_5_97_1","unstructured":"Sankyo D. Datopotamab deruxtecan new BLA submitted for accelerated approval in the U.S. for patients with Previously treated advanced EGFR-Mutated non-small cell lung cancer. 2024 Nov 12 press release. [accessed 2024 Nov 13]. https:\/\/daiichisankyo.us\/press-releases\/-\/article\/datopotamab-deruxtecan-new-bla-submitted-for-accelerated-approval-in-the-u-s-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell."},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01544"},{"key":"e_1_3_5_99_1","unstructured":"AstraZeneca. Datopotamab deruxtecan final overall survival results reported in patients with metastatic hr-positive HER2-low or negative breast cancer in TROPION-Breast01 phase III trial. 2024 Sep 23 press release. [accessed 2024 Nov 10]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.html#."},{"key":"e_1_3_5_100_1","unstructured":"AbbVie. AbbVie submits biologics license application to the FDA for telisotuzumab vedotin (teliso-v) in Previously treated non-small cell lung cancer. 2024 Sep 27 press release. [accessed 2024 Sep 30]. https:\/\/news.abbvie.com\/2024-09-27-AbbVie-Submits-Biologics-License-Application-to-the-FDA-for-Telisotuzumab-Vedotin-Teliso-V-in-Previously-Treated-Non-Small-Cell-Lung-Cancer."},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00720"},{"key":"e_1_3_5_102_1","unstructured":"Merck. Patritumab deruxtecan granted priority review in the U.S. for certain patients with Previously treated locally advanced or metastatic EGFR-Mutated non-Small cell lung cancer. 2023 Dec 22 press release. [accessed 2024 Nov 2]. https:\/\/www.merck.com\/news\/patritumab-deruxtecan-granted-priority-review-in-the-u-s-for-certain-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer\/."},{"key":"e_1_3_5_103_1","unstructured":"Merck. Patritumab deruxtecan BLA submission receives complete response letter from FDA due to inspection findings at third-party manufacturer. 2024 June 26 [accessed 2024 Nov 2]. https:\/\/www.merck.com\/news\/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer\/."},{"key":"e_1_3_5_104_1","unstructured":"Merck. Patritumab deruxtecan demonstrated statistically significant improvement in progression-free survival versus doublet chemotherapy in patients with locally advanced or metastatic EGFR-Mutated non-small cell lung cancer in HERTHENA-Lung02 phase 3 trial. 2024 Sep 17 press release. [accessed 2024 Nov 2]. https:\/\/www.merck.com\/news\/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression-free-survival-versus-doublet-chemotherapy-in-patients-with-locally-advanced-or-metastatic-egfr-mutated-non-small\/."},{"key":"e_1_3_5_105_1","unstructured":"Regeneron Pharmaceuticals Inc. Linvoseltamab BLA for treatment of relapsed\/refractory multiple myeloma accepted for FDA priority review. 2024 Feb 21 press release. [accessed 2024 Nov 2]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/linvoseltamab-bla-treatment-relapsedrefractory-multiple-myeloma."},{"key":"e_1_3_5_106_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron provides update on biologics license application for linvoseltamab. 2024 Aug 20 press release. [accessed 2024 Nov 2]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-provides-update-biologics-license-application-0\/."},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_5_108_1","unstructured":"Philogen S.p.A. Sun Pharmaceutical Industries Limited. Submission of Nidlegy\u2122 marketing authorization application validated by EMA. 2024 Jul 4 press release. [accessed 2024 Nov 2]. https:\/\/www.philogen.com\/philogen\/wp-content\/uploads\/2024\/07\/240623_Press_release_Nidlegy_MAA.pdf."},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9501"},{"key":"e_1_3_5_110_1","unstructured":"Kelun-Biotech Biopharmaceutical Co S. Ltd. interim results announcement for the six months ended June 30. 2024 June 30 press release. [accessed 2024 Oct 20]. https:\/\/www1.hkexnews.hk\/listedco\/listconews\/sehk\/2024\/0819\/2024081901322.pdf."},{"key":"e_1_3_5_111_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Interim report. 2024 [accessed 2024 Oct 20]. https:\/\/www1.hkexnews.hk\/listedco\/listconews\/sehk\/2024\/0919\/2024091900529.pdf."},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100617"},{"key":"e_1_3_5_113_1","unstructured":"Lepu Biopharma Co. Ltd. Acceptance of the new drug application and priority review granted by NMPA to MRG003 for the treatment of R\/M NPC. 2024 Sep 27 press release. [accessed 2024 Dec 3]. https:\/\/www1.hkexnews.hk\/listedco\/listconews\/sehk\/2024\/0927\/2024092700183.pdf."},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3578"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03110-7"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4092"},{"key":"e_1_3_5_117_1","unstructured":"Simcere Zaiming Pharmaceutical Co. Ltd. New drug application of suvemcitug for injection has been accepted by the china national medical products administration. 2024 Mar 20 press release. [accessed 2024 Oct 9]. https:\/\/en.simcere.com\/news\/detail.aspx?mtt=428."},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17suppl.LBA551"},{"key":"e_1_3_5_119_1","unstructured":"Medicine H. Hengrui medicine\u2019s ADC innovative drug ruikang trastuzumab for injection has been accepted for marketing approval and has been included in the priority review. 2024 Sep 14 press release. [accessed 2024 Nov 18]. https:\/\/www.hengrui.com\/media\/detail-631.html."},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01897-y"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2302"},{"key":"e_1_3_5_122_1","unstructured":"GSK. Third quarter 2024. 2024 Oct 30 press release. [accessed 2024 Nov 12]. https:\/\/www.gsk.com\/media\/11412\/q2-2024-results-announcement.pdf."},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673"},{"key":"e_1_3_5_124_1","unstructured":"GSK. GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps. 2024 Oct 14 press release. [accessed 2024 Oct 14]. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-positive-phase-iii-results-from-anchor-trials\/."},{"key":"e_1_3_5_125_1","unstructured":"Rock S. Scholar rock reports apitegromab meets primary endpoint in phase 3 SAPPHIRE study in patients with spinal muscular atrophy (SMA). 2024 Oct 7 press release. [accessed 2024 Oct 14]. https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-reports-apitegromab-meets-primary-endpoint-phase-3."},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1419791"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209151"},{"key":"e_1_3_5_128_1","unstructured":"Biosciences A. Annexon announces positive topline results from pivotal phase 3 trial for first-in-class C1q blocking antibody ANX005 in guillain-barr\u00e9 syndrome. 2024 June 4 press release. [accessed 2024 Sep 25]. https:\/\/ir.annexonbio.com\/news-releases\/news-release-details\/annexon-announces-positive-topline-results-pivotal-phase-3-trial."},{"key":"e_1_3_5_129_1","unstructured":"Annexon Biosciences. Corporate Presentation. 2024 Aug [accessed 2024 Nov 12]. https:\/\/ir.annexonbio.com\/static-files\/3870e9bb-e581-457d-bf6a-84c13ae6ccae."},{"key":"e_1_3_5_130_1","unstructured":"Otsuka Pharmaceutical Co. Ltd. (Otsuka) and Otsuka pharmaceutical development & commercialization inc. Otsuka provides update on sibeprenlimab an investigational monoclonal antibody for the treatment of IgA nephropathy in adults. 2024 Nov 19 press release. [accessed 2024 Nov 19]. https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2024\/20241119_1.html."},{"key":"e_1_3_5_131_1","unstructured":"Otsuka Pharmaceutical Development & Commercialization Inc. Otsuka pharmaceutical Co. Ltd. Otsuka announces positive interim results from the phase 3 trial of sibeprenlimab for the treatment of immunoglobulin a nephropathy in adults. 2024 Oct 22 press release. [accessed 2024 Nov 18]. https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2024\/20241022_1.html."},{"key":"e_1_3_5_132_1","unstructured":"Nordisk A\/S N. Investor presentation: first nine months of 2024. 2024 Nov 6 presentation. [accessed 2024 Nov 12]. https:\/\/investor.novonordisk.com\/q3-2024-presentation\/?page=183."},{"key":"e_1_3_5_133_1","unstructured":"Nordisk A\/S N. Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia a in the frontier 2 trial. 2024 May 13 press release. [accessed 2024 Sep 22]. https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=168515."},{"key":"e_1_3_5_134_1","unstructured":"Roche. YTD September 2024 sales. 2024 Oct 23 [accessed 2024 Nov 22]. https:\/\/assets.roche.com\/f\/176343\/x\/31805a2578\/irp231024.pdf."},{"key":"e_1_3_5_135_1","unstructured":"Myers Squibb B. Bristol Myers Squibb Q2 2024 results. 2024 Jul 26 press release. [accessed 2024 Sep 20]. https:\/\/www.bms.com\/assets\/bms\/us\/en-us\/pdf\/investor-info\/doc_financials\/quarterly_reports\/2024\/BMY-Q22024-Earnings-Press-Release.pdf."},{"key":"e_1_3_5_136_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.1697"},{"key":"e_1_3_5_137_1","doi-asserted-by":"crossref","unstructured":"Sanofi. Results Q3 2024. 2024 Nov 12 presentation [accessed 2024 Nov 12]. https:\/\/www.sanofi.com\/assets\/dotcom\/content-app\/events\/quaterly-results\/2024\/2024-q3-2024-results\/q3-2024-presentation-en.pdf.","DOI":"10.1016\/j.fopow.2024.02.009"},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00718-2023"},{"key":"e_1_3_5_139_1","unstructured":"Viridian Therapeutics Inc. Viridian therapeutics announces positive topline results from veligrotug (VRDN-001) phase 3 THRIVE clinical trial in patients with active thyroid eye disease. 2024 Sep 10 press release. [accessed 2024 Sep 11]. https:\/\/investors.viridiantherapeutics.com\/news\/news-details\/2024\/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Veligrotug-VRDN-001-Phase-3-THRIVE-Clinical-Trial-in-Patients-with-Active-Thyroid-Eye-Disease\/default.aspx."},{"key":"e_1_3_5_140_1","unstructured":"AstraZeneca. Clinical trials appendix Q3 2024 results update. 2024 Nov 12 company presentation [accessed 2024 Nov 20]. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2024\/h1\/H1-and-Q2-2024-results-presentation.pdf."},{"key":"e_1_3_5_141_1","unstructured":"Fortress Biotech Inc. Fortress biotech reports first Quarter 2024 financial results and recent corporate highlights. 2024 May 15 press release. [accessed 2024 Sep 27]. https:\/\/www.fortressbiotech.com\/investors\/news-events\/press-releases\/detail\/641\/fortress-biotech-reports-first-quarter-2024-financial."},{"key":"e_1_3_5_142_1","unstructured":"MoonLake Immunotherapeutics. Capital Markets Update. MoonLake immunotherapeutics presentation. 2024 Sep 11 [accessed 2024 Sep 18]. https:\/\/ir.moonlaketx.com\/static-files\/2b4ded14-cbe9-42fa-9ddd-56093302fc07."},{"key":"e_1_3_5_143_1","unstructured":"Rezolute. Inc. Rezolute: late-stage rare disease company treating hyperinsulinism. 2024 September presentation [accessed 2024 Sep 18]. https:\/\/d1io3yog0oux5.cloudfront.net\/_d5f9e5a53908f3fa8ab68e65cd128d31\/rezolutebio\/db\/693\/9992\/pdf\/RZLT+Corporate+Presentation_September+2024_.pdf."},{"key":"e_1_3_5_144_1","unstructured":"Oncology A. Interim results announcement for the six months ended June 30 2024. 2024 Aug 15 press release. [accessed 2024 Sep 18]. https:\/\/www.alphamabonc.com\/en\/uploads\/2024\/08\/172372714522178\/.pdf."},{"key":"e_1_3_5_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101470"},{"key":"e_1_3_5_146_1","unstructured":"Oncology A. Interim results announcement for the six months ended June 30 2024. 2024 Aug 15 press release. [accessed 2024 Sep 22]. https:\/\/www.alphamabonc.com\/en\/uploads\/2024\/08\/172372714522178.pdf."},{"key":"e_1_3_5_147_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00543-z"},{"key":"e_1_3_5_148_1","unstructured":"Genentech. Genentech provides update on phase II\/III skyscraper-06 study in metastatic non-squamous non-small cell lung cancer. 2024 Jul 3 press release. [accessed 2024 Nov 12]. https:\/\/www.gene.com\/media\/press-releases\/15029\/2024-07-03\/genentech-provides-update-on-phase-iiiii."},{"key":"e_1_3_5_149_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.245"},{"key":"e_1_3_5_150_1","unstructured":"Regulatory Focus. Cavazzoni urges proactive measures to avoid CRLs for biologics manufacturing issues. 2024 Aug 20 [accessed 2024 Nov 18]. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2024\/8\/cavazzoni-urges-proactive-measures-to-avoid-crls-f."}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2024.2443538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:44:30Z","timestamp":1765453470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2024.2443538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,22]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/19420862.2024.2443538"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2024.2443538","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2443538"}}